Tirzepatide, retatrutide, semaglutide, tesamorelin, MOTS-c and the other metabolic peptides, with the trial data and the safety signals.
· 22 min read
The tirzepatide peptide explained: how dual GIP and GLP-1 agonism works, what SURPASS and SURMOUNT found, and what testing shows about research vials.
· 21 min read
GLP-1 agonists like Semaglutide and Tirzepatide are reshaping peptide weight loss research. This covers mechanisms, real protocol structures, and what the evidence actually supports.
· 9 min read
Retatrutide is an investigational triple-agonist peptide with record weight-loss data. See what the research shows, its side effects, dosing, and why it is not FDA approved.
· 8 min read
Ozempic mania explained: How GLP-1 drugs became a global phenomenon, and what biohackers need to know. Full analysis inside.
· 11 min read
A clear, science-backed look at the MOTS-c peptide. How it works, what the research shows, side effects, timing, and where to get it for research.
· 13 min read
Tesamorelin is a GHRH analog studied for visceral fat reduction. What the research shows on body composition, metabolic health, safety, and prescription status.
· 12 min read
A research-backed breakdown of how GLP-1 receptor agonists affect the gallbladder and pancreas, including what the clinical data says about real-world risk.
